Nevertheless, we are confident that further improvements in patient outcomes can be achieved through investment in the areas of (a) molecular diagnostic tools, (b) variant and mutation testing, (c) therapeutic modality development, all of which will be required to optimise management of EML4‐ALK+ NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.